| Primary |
| Drug Abuse |
54.8% |
| Sedative Therapy |
6.0% |
| Drug Abuser |
4.3% |
| Pain |
4.3% |
| Induction Of Anaesthesia |
4.0% |
| Analgesic Therapy |
3.7% |
| General Anaesthesia |
3.7% |
| Antiretroviral Therapy |
3.0% |
| Postoperative Analgesia |
2.3% |
| Dermatitis Diaper |
2.0% |
| Off Label Use |
2.0% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Status Epilepticus |
1.7% |
| Sedation |
1.3% |
| Anaesthesia Procedure |
1.0% |
| Epidural Analgesia |
1.0% |
| Substance Use |
1.0% |
| Accidental Exposure To Product |
0.7% |
| Accidental Poisoning |
0.7% |
| Atrial Fibrillation |
0.7% |
|
| Urge Incontinence |
12.0% |
| Drug Abuse |
11.3% |
| Drug Toxicity |
7.5% |
| Hydronephrosis |
7.5% |
| Cystitis |
6.8% |
| Cystitis Ulcerative |
6.0% |
| Reduced Bladder Capacity |
6.0% |
| Off Label Use |
5.3% |
| Urinary Tract Disorder |
5.3% |
| Cystitis Interstitial |
3.8% |
| Drug Ineffective |
3.8% |
| Fall |
3.8% |
| Drug Screen Positive |
3.0% |
| Injury |
3.0% |
| Loss Of Consciousness |
3.0% |
| Self-medication |
3.0% |
| Blood Pressure Increased |
2.3% |
| Cardiac Arrest |
2.3% |
| Cystitis Noninfective |
2.3% |
| Hepatobiliary Disease |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
53.0% |
| Pain |
13.3% |
| Drug Use For Unknown Indication |
7.6% |
| General Anaesthesia |
6.0% |
| Induction Of Anaesthesia |
5.1% |
| Anaesthesia |
3.1% |
| Asthma |
2.1% |
| Multiple Sclerosis |
1.4% |
| Dermatitis Diaper |
1.2% |
| Hypertension |
1.2% |
| Off Label Use |
1.2% |
| Prophylaxis |
0.8% |
| Status Asthmaticus |
0.8% |
| Anaesthesia Procedure |
0.6% |
| Antibiotic Prophylaxis |
0.6% |
| Antiretroviral Therapy |
0.6% |
| Analgesic Therapy |
0.4% |
| Atrial Fibrillation |
0.4% |
| Headache |
0.4% |
| Infection Prophylaxis |
0.4% |
|
| Venoocclusive Liver Disease |
49.5% |
| Venoocclusive Disease |
14.3% |
| Dilatation Intrahepatic Duct Acquired |
5.5% |
| Hepatotoxicity |
3.3% |
| Acute Generalised Exanthematous Pustulosis |
2.2% |
| Alanine Aminotransferase Increased |
2.2% |
| Bradycardia |
2.2% |
| Generalised Erythema |
2.2% |
| Hepatitis Acute |
2.2% |
| Liver Function Test Abnormal |
2.2% |
| Partial Seizures |
2.2% |
| Sinus Tachycardia |
2.2% |
| Stress Cardiomyopathy |
2.2% |
| Anaphylactic Shock |
1.1% |
| Blood Alkaline Phosphatase Increased |
1.1% |
| Blood Bilirubin Increased |
1.1% |
| Circulatory Collapse |
1.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
1.1% |
| Erythema |
1.1% |
| Exposure During Pregnancy |
1.1% |
|
| Concomitant |
| Prophylaxis |
10.6% |
| Product Used For Unknown Indication |
10.6% |
| Sedation |
9.4% |
| Fluid Replacement |
8.9% |
| Infection |
7.5% |
| Ureteral Stent Insertion |
6.6% |
| Ureteral Stent Removal |
6.6% |
| Drug Use For Unknown Indication |
4.4% |
| Cancer Pain |
4.1% |
| Diuretic Therapy |
4.1% |
| Infection Prophylaxis |
3.7% |
| Pyrexia |
3.1% |
| Ewing's Sarcoma |
3.1% |
| Insomnia |
2.9% |
| Prophylaxis Against Graft Versus Host Disease |
2.8% |
| Anticoagulant Therapy |
2.7% |
| Pain |
2.7% |
| Neoplasm Malignant |
2.4% |
| Electrolyte Substitution Therapy |
2.2% |
| Anaesthesia |
1.7% |
|
| Respiratory Failure |
20.3% |
| Coma |
7.2% |
| White Blood Cell Count Increased |
7.2% |
| Encephalopathy |
5.8% |
| Hepatic Function Abnormal |
5.8% |
| Viral Infection |
5.8% |
| Anaphylactic Shock |
4.3% |
| Rhabdomyolysis |
4.3% |
| Somnolence |
4.3% |
| Tachycardia |
4.3% |
| Venoocclusive Liver Disease |
4.3% |
| Coagulation Time Abnormal |
2.9% |
| Drug Ineffective |
2.9% |
| Dysphagia |
2.9% |
| Hepatic Failure |
2.9% |
| Injection Site Thrombosis |
2.9% |
| Interstitial Lung Disease |
2.9% |
| Liver Disorder |
2.9% |
| Nikolsky's Sign |
2.9% |
| Pancytopenia |
2.9% |
|
| Interacting |
| Antiretroviral Therapy |
57.1% |
| Asthma |
14.3% |
| Hypertension |
14.3% |
| Substance Use |
14.3% |
|
| Hepatobiliary Disease |
100.0% |
|
